The public relations departments at American pharmaceutical manufacturers can’t be too pleased about the results of a new Harris Poll out this week that shows only nine percent of U.S. consumers believe “pharmaceutical and biotechnology companies put patients over profits.” Read More »
AzurRx BioPharma has partnered with Mayoly Spindler to begin a Phase II clinical trial to assess the safety and effectiveness of MS1819-SD for the treatment of patients who have exocrine pancreatic insufficiency that is the result of chronic pancreatitis. Read More »
Dr. Giovanni Caforio has been named the Chairman of the Board for Bristol-Myers Squibb's board of directors, effective May 2 at the annual shareholder’s meeting. Read More »
Pfizer will expand its Advancing Science through Pfizer Investigator Research Exchange program next year. Read More »
Pfizer and its partner Avillion LLP have announced the results from the BFORE clinical study. Read More »
Pfizer's executive vice president and president of global supply Anthony Maddaluna is retiring after 41 years with the company. Read More »
Bristol-Myers Squibb and Innate Pharma have released the interim effectiveness analysis of its Phase 1/2 trial involving the lirilumab and Opdivo combination. Read More »
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that Opdivo from Bristol-Myers Squibb Co. be approved to treat relapsed or refractory classical Hodgkin lymphoma in adult patients who have previously received autologous stem cell transplant and been treated with brentuximab vedotin. Read More »
Pfizer has released data from its Phase 1b clinical trial involving INLYTA, which has been combined with pembrolizumab, a PD-1 checkpoint inhibitor known as KEYTRUDA, in patients who have advanced renal cell carcinoma (RCC) that have yet to undergo treatment. Read More »
Pfizer has released results from its Phase 3 S-TRAC clinical study involving the assessment of SUTENT as an adjuvant therapy. Read More »
Pfizer has released data from its Phase 1b INLYTA clinical trial in which the drug is combined with pembrolizumab, a PD-1 inhibitor called KEYTRUDA, and marketed by Merck. Read More »
Anavex Life Sciences Corp. has entered into a collaborative agreement with Ariana Pharma to allow Anavex to use Ariana's proprietary Knowledge, Extraction, Management stratification technology to expedite the clinical development timelines of its ANAVEX 2-73 Phase 2/3 trial. Read More »
Regeneron Pharmaceutical's Phase 2 CAPELLA trial has turned in positive results. Read More »
Pfizer Inc. announced last week that its study to assess the safety, efficiency and immunogenicity of PF-06438179 called REFLECTIONS B537-02 has met its primary endpoint. Read More »
Antibody product is a potential treatment for Huntington's Disease. Read More »
Pfizer Inc. has announced that it has reached an agreement with AstraZeneca for the acquisition of the development and commercialization rights to its late-stage small molecule anti-infectives business. Read More »
TG Therapeutics Inc. recently announced that it has received orphan drug designation for TG-1101, otherwise known as ublituximab, from the U.S. Food and Drug Administration (FDA). Read More »
Phase III trial produces positive results in treating primary biliary cholangitis with Ocaliva. Read More »
Pfizer Inc. has announced that analysis of data from three studies involving VYNDAQEL have been published. Read More »
Bamboo research is focused on gene therapy for neuromuscular and central nervous system conditions. Read More »
Alerts Sign-up
